Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aliskiren. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN known ✓ | P00797 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aliskiren SCHEMBL3476540 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL3397036 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL2478013 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL29521564 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL3476535 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL3476537 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL13320734 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL13351616 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL7965529 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL6854403 | 1.00 | REN (1.00) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122084352-A | Preparation method and kit of aliskiren blue-alizarin red bone double-dyeing transparent fish bone specimen based on quantitative optimization | — | 2026-05-26 | — | — | CN | claimed |
| US-20250302887-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-10-02 | — | — | US | claimed |
| CN-120036301-A | Method for manufacturing transparent fish specimen and transparent fish specimen | 东兴海关综合技术服务中心 | 2025-05-27 | — | — | CN | claimed |
| CN-119935694-A | Multiple special staining analysis method for bone tissue and application thereof | 北京大学第三医院（北京大学第三临床医学院） | 2025-05-06 | — | — | CN | claimed |
| US-20250090602-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-03-20 | — | — | US | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| US-20240299465-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2024-09-12 | — | — | US | claimed |
| CN-117871219-A | Dyeing liquid for urine tangible analysis and use method thereof | 迪瑞医疗科技股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| US-7910774-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | claimed |
| EP-2191823-A1 | Methods for improving bioavailability of a renin inhibitor | Novartis Ag (CH) | 2010-06-02 | — | — | EP | claimed |
| EP-2152266-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | Ironwood Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | claimed |
| EP-2080754-A2 | Organic compounds | Novartis Ag (CH) | 2009-07-22 | — | — | EP | claimed |
| WO-2008137318-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| US-20080207921-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | claimed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | claimed |
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | claimed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | claimed |
| EP-0678503-A1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | REN 970/4885 |
| US-20080207921-A1 | Organic Compounds | REN, AGTR1, AGT | REN 1/4885 |
| US-20250302887-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | NOS2, LPO, OAT | REN 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.